▼ -41.92% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Morphic in the last 3 months. The average price target is $43.50, with a high forecast of $50.00 and a low forecast of $37.00. The average price target represents a -41.92% upside from the last price of $74.90.
The current consensus among 3 polled investment analysts is to buy stock in Morphic.
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidates in clinical development are MORF-720, a selective oral avÃ6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC); and MORF-057, a a4Ã7 specific integrin inhibitor for the treatment of inflammatory bowel disease (IBD). The company is also developing MR Ã6 #2, a selective avÃ6 specific integrin inhibitor to treat IPF and PSC; and avÃ1 integrin for the treatment of fibrosis. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with SchrÃ¶dinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics; and drug discovery research collaboration with HitGen Inc. to identify small molecule leads against targets specified by the company. The company was founded in 2014 and is based in Waltham, Massachusetts.